Table 5.
GMT and percentage of subjects with a titre ≥40 on day 43 for NT50 by PNA against Wuhan strain and three variants of concern.
| 1 µg S | 1 µg S+CpG | 3 µg S | 3 µg S+CpG | 10 µg S | Placebo | ||
|---|---|---|---|---|---|---|---|
| Wuhan | GMT |
n = 32 228·81 (161·74–323·69) |
n = 31 239·47 (159·27–360·06) |
n = 30 311·76 (187·56–518·18) |
n = 33 482·42 (350·08–664·77) |
n = 34 887·99 (600·72–1312·62) |
n = 33 5·89 (4·64–7·48) |
| titre ≥40 |
N = 34 34 (100%) (89·7–100) |
N = 33 31 (93·9%) (79·8–99·3) |
N = 33 32 (97·0%) (84·2–99·9) |
N = 33 33 (100%) (89·4–100) |
N = 35 35 (100%) (90·0–100) |
N = 34 2 (5·9%) (0·7–19·7) |
|
| P·1 | GMT |
n = 31 45·33 (32·18–63·85) |
n = 31 74·06 (48·99–111·97) |
n = 30 111·28 (72·06–171·83) |
n = 33 150·59 (111·15–204·03) |
n = 34 167·14 (120·63–231·58) |
n = 33 5·57 (4·47–6·94) |
| titre ≥40 |
N = 31 15 (48·4%) (30·2 – 66·9) |
N = 31 29 (74·2%) (55/4 – 88·1) |
N = 30 24 (80·0%) (61·4 – 92·3) |
N = 33 29 (87·9%) (71·8 – 96·6) |
N = 34 (32 (94·9%) (80·3 – 99·3) |
N = 33 1 (3·0%) (0·1 – 5·8) |
|
| B·1·351 | GMT |
n = 32 21·00 (15·12–29·18) |
n = 30 32·34 (22·13 - 47·24) |
n = 30 37·43 (24·77 - 56·56) |
n = 33 40·07 (28·09 −57·17) |
n = 34 43·47 (31·55 - 59·89) |
n = 33 6·12 (4·90 - 7·64) |
| titre ≥40 |
N = 32 5 (15·6%) (5·3 – 32·8) |
N = 30 15 (50·0%) (31·3 −68·7) |
N = 30 13 (43·3%) (30·8 - 66·5) |
N = 33 16 (48·5%) (30·8 – 66·5) |
N = 34 20 (58·8%) (40·7 – 75·4) |
N = 33 1 (3·0%) (0·1 – 15·8) |
|
| B.1.617.2 | GMT | N.D. | N.D. |
n = 29 95·07 (59·64–151·52) |
N.D. | N.D. | N.D. |
| titre ≥40 | N.D. | N.D. |
N = 29 20 (69·0%) (49·2–84.7) |
N.D. | N.D. | N.D. |
N.D. = not done.